 |
 |
|
 |
 |
Comments on Paper and Primary News |
 |
  |
| |
Primary News: Early Casualty, Neurogenesis Cripples Cognition in AD Mice
Comment by: Felix Hernandez
|
 |
 |
Submitted 23 March 2010
| Permalink
|
Posted 23 March 2010
|
 |
 |
We have previously published that doublecortin positive cells also express hyperphosphorylated tau (Fuster-Matanzo et al., 2009). Thus, we demonstrated that new neurons generated in the subgranular zone express tau in a hyperphosphorylated form. Phospho-tau expression colocalized with doublecortin but not with glial fibrillary acidic protein, Ki67 or calbindin. The same was observed in the subventricular zone. Tau knockout mice did not show a significant decrease in the number of doublecortin-positive cells, although a deficit in migration was observed. These findings suggest that tau phosphorylation in doublecortin-positive cells is involved in normal migration of new neurons.
References: Fuster-Matanzo A, de Barreda EG, Dawson HN, Vitek MP, Avila J, Hernández F. Function of tau protein in adult newborn neurons. FEBS Lett. 2009 583(18):3063-8. Abstract
View all comments by Felix Hernandez
|
 |

|
| |
Primary News: Early Casualty, Neurogenesis Cripples Cognition in AD Mice
Comment by: J. Lucy Boyd
|
 |
 |
Submitted 24 March 2010
| Permalink
|
Posted 24 March 2010
|
 |
 |
I recommend this paper
|
 |

|
| |
Primary News: Early Casualty, Neurogenesis Cripples Cognition in AD Mice
Comment by: Thomas Bayer, Oliver Wirths
|
 |
 |
Submitted 8 April 2010
| Permalink
|
Posted 8 April 2010
|
 |
 |
Whether or not physical activity and/or enriched environment could have a potential therapeutic effect in patients with Alzheimer disease (AD) is usually assessed in transgenic mouse models. There is no doubt that in wild-type mice, both physical activity and enriched environment lead to increased neurogenesis in some brain areas, e.g., the dentate gyrus. In contrast, the situation is much less clear in APP transgenic mouse models.
In a recent study, we analyzed neurogenesis in APP/PS1KI mice and quantified the number of doublecortin (DCX)-positive neurons in the subgranular zone of the dentate gyrus (Cotel et al., 2010). Already at the age of two months, a significantly reduced number of DCX-positive neurons were detected in APP/PS1KI mice compared to age-matched wild-type mice. This is the time point when the first amyloid plaques become apparent. In good agreement with a previous study (Faure et al., 2009), neurogenesis was almost completely absent by the age of six months. Interestingly, this loss of neurogenesis could not be modified by keeping the mice in an enriched...
Read more
Whether or not physical activity and/or enriched environment could have a potential therapeutic effect in patients with Alzheimer disease (AD) is usually assessed in transgenic mouse models. There is no doubt that in wild-type mice, both physical activity and enriched environment lead to increased neurogenesis in some brain areas, e.g., the dentate gyrus. In contrast, the situation is much less clear in APP transgenic mouse models.
In a recent study, we analyzed neurogenesis in APP/PS1KI mice and quantified the number of doublecortin (DCX)-positive neurons in the subgranular zone of the dentate gyrus (Cotel et al., 2010). Already at the age of two months, a significantly reduced number of DCX-positive neurons were detected in APP/PS1KI mice compared to age-matched wild-type mice. This is the time point when the first amyloid plaques become apparent. In good agreement with a previous study (Faure et al., 2009), neurogenesis was almost completely absent by the age of six months. Interestingly, this loss of neurogenesis could not be modified by keeping the mice in an enriched environment for a four-month period (from two to six months), although a significant increase in the number of DCX-positive neurons was detected in wild-type mice, underscoring the validity of the enrichment paradigm. Moreover, neuron loss in the CA1 region of the hippocampus of six-month-old APP/PS1KI mice (Breyhan et al., 2009) was not ameliorated by four months of enriched housing.
It is difficult to draw clear-cut conclusions for the human situation as environmental enrichment produced variable outcomes, probably due to differences in the AD mouse models that have been previously studied. The APP/PS1KI model represents a model for mild to severe AD. It shows early behavioral deficits starting at two months of age with fast deterioration. Therefore, our data might suggest that physical activity and enriched environment may only be beneficial in patients with mild cognitive impairment (or even earlier, before symptoms appear) and not in patients with early AD.
References: Cotel M.C., Jawhar S, Christensen D.Z., Bayer T.A., Wirths O. (2010). Environmental enrichment fails to rescue memory deficits, neuron loss and neurogenesis in APP/PS1KI mice. Neurobiology of Aging. Abstract
Faure A., Verret L., Bozon B., El Tannir El Tayara N., Ly M., Kober F., Dhenain M., Rampon C., Delatour B. (2009). Impaired neurogenesis, neuronal loss, and brain functional deficits in the APPxPS1-Ki mouse model of Alzheimer’s disease. Neurobiology of Aging. Abstract
Breyhan H., Wirths O., Duan K., Marcello A., Rettig J., Bayer T.A. (2009). APP/PS1KI bigenic mice develop early synaptic deficits and hippocampus atrophy. Acta Neuropathologica, 117 (6): 677-685. Abstract
View all comments by Thomas Bayer
View all comments by Oliver Wirths
|
 |
 |
| |
Submit a Comment on this Paper |
 |
 |
 |
 |
| |
 |
 |
| |
REAGENTS/MATERIAL:
The following primary antibodies were used in this study:
mouse monoclonal anti-BrdU (85-2C8) (Novocastra, Newcastle, United Kingdom);
early neuronal differentiation marker goat anti-doublecortin DCX (Santa Cruz Biotechnology, Santa Cruz, CA);
rabbit anti-PS1 NTF polyclonal (a generous gift from Dr. Gopal Thinakaran);
mouse monoclonal anti-human Aβ/APP monoclonal antibodies (6E10) (Chemicon, Billerica, MA; [discontinued]) for Aβ and hAPP CTFs;
369 mouse anti-APP (a generous gift from Dr. Sangram S. Sisodia) [for all CTFs];
PHF-1 mouse monoclonal anti-phosphorylated tau (Ser396 and Ser404) (PHF-1; Otvos et al.,1994; generous gift from Scott Brady and Gustavo Pigino);
mouse monoclonal anti-tau (Tau-5) (Chemicon);
R1 rabbit anti-tau polyclonal (a generous gift from Dr. Lester Binder);
rabbit anti-glial fibrillary acidic protein (GFAP) (Dako, Glostrup, Denmark),
mouse monoclonal anti-NeuN (A60) (Chemicon);
mouse monoclonal anti-actin (Chemicon)
and mouse monoclonal anti-TUJ-1/βIII tubulin (5G8) (Promega, Madison, WI).
To examine alterations in tau phosphorylation, we used AT8 antibodies that require tau protein to be phosphorylated at both serine 202 and threonine 205 (Goedert et al., 1995).
|
|
|
 |